Attempting to lift the veil of secrecy over AIMS-2

News

Written by: Panda Mery, Dinah Murray & Kabie Brook

The Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) was launched as the largest ever grant given to autism research on June 18th. Two weeks ago, we wrote some questions about this project and the autistic representation and monitoring, if any. Dr James Cusack, Director of Science, Autistica wrote a response that answered only some of our questions. Some people commented on both these posts (below each). Continue reading

Advertisements

Response from Dr. James Cusack to concerns regarding Autistica’s involvement in AIMS-2

News

Thank you to Panda, Dinah and Kabie for their post and to Damian for the opportunity to post here. It’s really good to have a nuanced discussion about Autistica’s involvement in AIMS-2-TRIALS. We are taking on board a variety of views, some critical, some undecided and some very supportive. All of these views are valid and will inform how we move forward. Continue reading

Critical Perspectives on Pathological Demand Avoidance (PDA)

Events

A PARC meeting will be held at London South Bank University (LSBU) from 4.30-7pm on 15th May, room VG-10 in the K2 building, Keyworth Street. The meeting will involve a number of presentations critically reflecting upon Pathological Demand Avoidance (PDA). If you would like to attend please email: damianmilton.sociology@yahoo.com

Continue reading